China probes of Glaxo, Sanofi, others put big chill on key growth market

Eric Palmer

The recent, and very public, Chinese investigation into bribery allegations against GlaxoSmithKline and has doctors running scared, making it tough for everyone to sell drugs there.

FiercePharma News

Share This Post

Related Articles

Leave a Reply

© 2018 Global Regulatory Science. All rights reserved. Site Admin · Entries RSS · Comments RSS